AIM ImmunoTech Inc logo

AIM ImmunoTech Inc

AMEX:AIM (USA)  
$ 0.43 +0.0055 (+1.31%) 10:08 PM EST
At Loss
P/B:
2.24
Market Cap:
$ 21.59M
Enterprise V:
$ 9.65M
Volume:
255.65K
Avg Vol (2M):
260.20K
Also Trade In:
Volume:
255.65K
At Loss
Avg Vol (2M):
260.20K

Business Description

Description
AIM ImmunoTech Inc is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders and viral and cancer diseases. AIM's flagship products include Ampligen (Rintatolimod), a drug of large macromolecular RNA molecules for cancer and viral diseases, and the drug Alferon N Injection for a category of STD infection. Clinical trials of Ampligen include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer, and triple-negative metastatic breast cancer. It is also advancing Ampligen as a potential treatment for COVID-19. FDA has authorized the first human trial assessing the safety and effectiveness of Ampligen in combination with interferon alfa-2b, in cancer patients with COVID-19.
Name Current Vs Industry Vs History
Cash-To-Debt 18.2
Equity-to-Asset 0.53
Debt-to-Equity 0.07
Debt-to-EBITDA -0.02
Interest Coverage N/A
N/A
N/A
Piotroski F-Score 3/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -32.74
Distress
Grey
Safe
Beneish M-Score -7.56
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 28.19
9-Day RSI 38.78
14-Day RSI 44.05
6-1 Month Momentum % 1.49
12-1 Month Momentum % -12.74

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 1.68
Quick Ratio 1.68
Cash Ratio 1.51
Days Sales Outstanding 1590.1
Days Payable 22112.05

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -5.2
Shareholder Yield % -2.69

Financials (Next Earnings Date:2024-05-15 Est.)

AIM's 30-Y Financials
Income Statement Breakdown
No Enough Data
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Gurus Latest Trades with AMEX:AIM

No Available Data

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015

AIM ImmunoTech Inc Executives

Details

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 0.202
EPS (TTM) ($) -0.6
Beta 1.19
Volatility % 59.53
14-Day RSI 44.05
14-Day ATR ($) 0.055313
20-Day SMA ($) 0.48756
12-1 Month Momentum % -12.74
52-Week Range ($) 0.3201 - 0.7487
Shares Outstanding (Mil) 50.75

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 3
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

AIM ImmunoTech Inc Filings

Filing Date Document Date Form
No Filing Data

AIM ImmunoTech Inc Stock Events

Financials Calendars
Event Date Price($)
No Event Data

AIM ImmunoTech Inc Frequently Asked Questions

What is AIM ImmunoTech Inc(AIM)'s stock price today?
The current price of AIM is $0.43. The 52 week high of AIM is $0.75 and 52 week low is $0.32.
When is next earnings date of AIM ImmunoTech Inc(AIM)?
The next earnings date of AIM ImmunoTech Inc(AIM) is 2024-05-15 Est..
Does AIM ImmunoTech Inc(AIM) pay dividends? If so, how much?
AIM ImmunoTech Inc(AIM) does not pay dividend.

Press Release

Subject Date
No Press Release

Headlines

See More
  • 1
No news.
  • 1